JDD January 2021 Issue Highlights: From COVID-19 Vaccine to Facial Rejuvenation
The January issue of the Journal of Drugs in Dermatology focuses on Aesthetics Treatments, featuring an outstanding line-up of original articles from COVID-19 vaccine to facial rejuvenation. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
Aesthetic Office Disaster Preparedness and Response Plan is a proactive approach for aesthetic treatment offices to manage a …
The January issue of the Journal of Drugs in Dermatology focuses on Aesthetics Treatments, featuring an outstanding line-up of original articles from COVID-19 vaccine to facial rejuvenation. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
Aesthetic Office Disaster Preparedness and Response Plan is a proactive approach for aesthetic treatment offices to manage a … Continue reading "JDD January 2021 Issue Highlights: From COVID-19 Vaccine to Facial Rejuvenation"
Actinic keratoses represent the most common dermatologic diagnosis in patients older than 45 years old in the United States and account for 5.2 million visits annually.1 Cutaneous field cancerization represents areas with a high burden of both clinical and subclinical actinic damage. Cryotherapy can often be combined with topical chemotherapy for a synergistic approach. We continue our series, The … 
The November issue of the Journal of Drugs in Dermatology focuses on the topics of Lasers, Light Sources, and Devices, featuring an outstanding line-up of original articles. Straight from the JDD Editor’s desk, we share this month’s issue highlights
The Guest Editorial by Dr. Macrene Alexiades focuses on the growing body of objective quantifiable data demonstrating time-sensitive improvemen … 
In this month’s installment of our Therapeutic Cheat Sheet Series, we will review the topical immunomodulatory agent imiquimod. Originally approved for the treatment of external genital warts, FDA approval has expanded to include use as field therapy for actinic keratoses as well as treatment of superficial basal cell carcinomas. Here’s what you need to know about imiquimod.
[caption id=" … 
Although this may be a big assumption, I would venture to guess that training in the management of keloids has, for many residents, consisted primarily of topical and intralesional therapies—namely steroids and silicone. While steroids and silicone may be a fantastic name for a reality television show about the exciting lives of female bodybuilders, in real life it can be a pretty unimaginative …